Efficacy of post‐first‐line agents for advanced gastrointestinal stromal tumors following imatinib failure: A network meta‐analysis

BACKGROUND: Imatinib is the standard first‐line treatment for advanced gastrointestinal stromal tumors (GISTs); however, most patients eventually develop imatinib resistance, leading to considerable clinical challenges. Few direct comparisons have been made between different post‐first‐line therapie...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Kehan, Zhang, Hu, Shu, Mingrong, Wang, Xingyue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278495/
https://www.ncbi.nlm.nih.gov/pubmed/37084005
http://dx.doi.org/10.1002/cam4.5912

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10278495/
https://www.ncbi.nlm.nih.gov/pubmed/37084005
http://dx.doi.org/10.1002/cam4.5912

Ejemplares similares